Despite a very challenging economic climate in 2009, MorphoSys became a stronger and more mature Company in almost every respect.
Letter of the CEO
Increasingly, the Company’s pipeline is taking center stage. Altogether, our partnered pipeline of HuCAL-based drugs increased from 55 at the beginning of 2009 to 65 at year end.
Product-Pipeline
Our ability to fund all of our internal development activities while remaining profitable is a unique feature of our business model, which sets us apart from the majority of high risk, cash-burning biopharmaceutical companies.
Consolidated statement of operations (IFRS)
